Ashfield Capital Partners’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Ashfield Capital Partners’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$1.25M	Sell	15,799 -329	-2%	-$27.7K	0.11%	121
2022 Q2	$1.2M	Sell	16,128 -3,054	-16%	-$229K	0.09%	126
2022 Q1	$1.72M	Sell	19,182 -2,165	-10%	-$200K	0.11%	122
2021 Q4	$2.39M	Sell	21,347 -3,909	-15%	-$471K	0.15%	104
2021 Q3	$3.17M	Buy	25,256 +1,275	+5%	+$164K	0.23%	85
2021 Q2	$3.25M	Buy	23,981 +6,068	+34%	+$798K	0.23%	85
2021 Q1	$2.43M	Sell	17,913 -935	-5%	-$140K	0.19%	94
2020 Q4	$2.65M	Buy	18,848 +540	+3%	+$69.2K	0.22%	86
2020 Q3	$2.04M	Buy	18,308 +10	+0.1%	+$1.12K	0.19%	97
2020 Q2	$2.05M	Sell	18,298 -3,607	-16%	-$355K	0.2%	93
2020 Q1	$1.7M	Buy	21,905 +2,715	+14%	+$240K	0.21%	98
2019 Q4	$1.82M	Sell	19,190 -5,510	-22%	-$477K	0.18%	106
2019 Q3	$1.88M	Buy	+24,700	New	+$2.05M	0.2%	102
2019 Q2	–	Sell	-26,396	Closed	-$2.25M	–	85
2019 Q1	$2.39M	Buy	26,396 +4,387	+20%	+$373K	0.26%	88
2018 Q4	$1.58M	Sell	22,009 -13,219	-38%	-$1.07M	0.21%	111
2018 Q3	$3.38M	Buy	35,228 +9,705	+38%	+$941K	0.38%	71
2018 Q2	$2.43M	Buy	25,523 +15,241	+148%	+$1.4M	0.3%	83
2018 Q1	$902K	Buy	+10,282	New	+$939K	0.12%	150

Other funds holding XBI

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Ashfield Capital Partners's XBI Position: Q3 2022 in Review

Ashfield Capital Partners reduced its State Street SPDR S&P Biotech ETF (XBI) stake by 2% in Q3 2022, selling an estimated $27.7K and leaving 15,799 shares worth $1.25M. The position accounts for 0.11% of the portfolio, ranked #121.

Ashfield Capital Partners first reported a position in XBI in Q1 2018 and has held it in 18 quarters since. The position peaked at $3.38M in Q3 2018. 704 funds tracked by Wall St. Rank hold XBI as of Q3 2022.

Ashfield Capital Partners held 15,799 shares of State Street SPDR S&P Biotech ETF worth $1.25M as of Q3 2022.
Ashfield Capital Partners sold 329 State Street SPDR S&P Biotech ETF shares in Q3 2022, an estimated $27.7K.
State Street SPDR S&P Biotech ETF made up 0.11% of Ashfield Capital Partners's portfolio in Q3 2022, its #121 holding.
Ashfield Capital Partners first reported a position in State Street SPDR S&P Biotech ETF in Q1 2018 and has held it in 18 quarters since.
Ashfield Capital Partners's State Street SPDR S&P Biotech ETF position peaked at $3.38M in Q3 2018.
704 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2022.

Based on Ashfield Capital Partners's 13F filing for Q3 2022, filed 10 Nov 2022.